insurance coverage for glp 1 drugs Medicaid of and Spending on GLP-1s How Do GLP-1 Medications Work
Description
When heterogeneity was obvious (I 2 50 %), a random-effects model was used to summarize the RRs
The question isn't whether oral GLP-1 therapy will reach the mass market
The overall heterogeneity for renal outcome was I 2 = 42.3% (95% uncertainty intervals, 0 and 68.0%) (moderate) (Additional file 1: Table S3) with no evidence of publication bias
We employ NCI-H716 * and STC-1 cell lines, well-characterized models respectively for human and murine intestinal L-cells
Mojsov S
